Colorectal cancer persists as one of the most lethal malignancies worldwide, accounting for nearly ten percent of all cancer diagnoses. Particularly alarming is the trend of increasing mortality among individuals under the age of 50, whereby CRC has emerged as the leading cause of cancer-related death. A pivotal challenge in managing colorectal cancer is the propensity of tumors to metastasize, with up to half of the patients developing secondary tumors in distant organs, especially the liver. These liver metastases drastically decrease survival chances, posing a major clinical hurdle.

Intriguingly, the survival outcomes amongst patients harboring liver metastases vary dramatically depending on the nature of the tumor-liver interface. Encapsulated metastases, characterized by distinct separation from healthy liver tissue, correspond to significantly higher five-year survival rates of approximately 73%. Conversely, patients whose tumors exhibit replacement metastases, where cancer cells intricately infiltrate and co-opt normal liver parenchyma, endure much lower survival rates dipping below 44%. Despite this stark clinical dichotomy, the mechanisms steering the development of these invasive replacement metastases remain largely obscure, and effective targeted therapies are lacking.

A pivotal stride in addressing this knowledge gap emerged from the work led by Prof. Sarah-Maria Fendt at the VIB-KU Leuven Center for Cancer Biology. Her team identified liver steatosis, commonly known as fatty liver disease—a lifestyle-associated metabolic disorder—as a significant determinant that predisposes patients to develop the more virulent replacement type of liver metastases. The epidemic rise in fatty liver prevalence, fueled largely by obesity and metabolic syndrome, underscores the global relevance of this finding.

The study integrated meticulous analysis of patient-derived samples and advanced experimental models, revealing that fatty liver alters the biochemical milieu within the liver, creating favorable conditions for aggressive metastatic growth. The research demonstrated that increased hepatic fat content stabilizes MYC, a critical oncogenic transcription factor implicated in numerous cancers. Stabilized MYC upregulates proline biosynthesis, an amino acid essential for collagen synthesis. The surplus collagen-rich extracellular matrix forms a scaffold that facilitates tumor invasion and coexistence with normal liver tissue, thus driving the formation of replacement metastases.

This mechanistic insight dramatically reframes our understanding of tumor behavior in metabolically altered environments. As Prof. Fendt elaborated, the fatty liver doesn’t just serve as a passive backdrop; instead, it actively remodels the tumor microenvironment by supplying both the molecular cues and structural substrates that tumors exploit to enhance their invasiveness. This highlights the fundamental notion that cancer progression is a multi-faceted dialogue between tumor cells and their host tissues.

From a clinical standpoint, the implications of these discoveries are profound. Drugs targeting the MYC pathway are already under clinical evaluation, primarily for their safety profiles. However, their therapeutic efficacy hinges on the ability to selectively identify patients who will derive the greatest benefit. The current study indicates that patients suffering from fatty liver and replacement metastases represent the ideal candidates for MYC-targeted therapies. This stratification strategy promises to enhance the success rate of clinical trials by aligning treatment with underlying disease biology.

Precision in patient selection is thus elevated as a critical objective for oncological research and practice. The patient’s metabolic profile, particularly liver fat content, could serve as a biomarker guiding treatment decisions and predicting metastatic potential. This approach can potentially minimize the administration of ineffective therapies, sparing patients from undue side effects while accelerating the development of successful interventions.

Beyond the identification of patient subsets, the study pioneers new therapeutic avenues by demonstrating that interfering with various nodes of the fatty liver metastasis axis can substantially curtail aggressive tumor growth. Targeting MYC stabilization, proline synthesis, or collagen deposition each yielded promising results in experimental and patient-derived liver metastasis models. This multipronged strategy may pave the way for combinatorial treatments tailored to the metabolic state of patients, transforming the therapeutic landscape for CRC metastases.

The integration of metabolic health into cancer care represents a seismic shift in how clinicians and researchers view tumor biology. Traditionally, treatment paradigms have focused predominantly on tumor-intrinsic factors. This study underscores the necessity of acknowledging the systemic and organ-specific environments that shape cancer progression. As Dr. Yiming Peng-Winkler, the study’s first author, highlighted, the future of oncology lies in embracing this holistic perspective to design therapies that are simultaneously precise and powerful.

The broader implications extend beyond colorectal cancer and fatty liver disease. Metabolic disorders are rising globally, and their impact on cancer biology may be pervasive across different tumor types and metastatic sites. This research provides a critical roadmap for exploring how metabolic alterations sculpt the tumor ecosystem, thereby informing diagnostics, prognostics, and therapeutic innovation on a wider scale.

Ultimately, this paradigm shift heralds a new era where metabolic health is placed at the forefront of cancer treatment strategies. The findings illustrate that addressing metabolic dysfunction is not only a preventive measure but also a vital component of therapeutic intervention. By bridging the gap between metabolic diseases and oncology, this research opens unprecedented opportunities to improve outcomes for patients grappling with the most formidable manifestations of metastatic cancer.

Subject of Research: Animals
Article Title: Steatosis shapes prognosis-defining liver metastasis heterogeneity in CRC
News Publication Date: 1 July 2026
Keywords: colorectal cancer, fatty liver disease, liver metastases, tumor microenvironment, MYC protein, proline biosynthesis, collagen formation, metabolic health, cancer progression, targeted therapy, patient stratification, metastasis heterogeneity

Central to this symposium is the exploration of protein kinase specificity, a subject extensively addressed by Lewis Cantley, PhD, from the Dana-Farber Cancer Institute. Protein kinases, enzymes critical in cell signaling and regulation, have emerged as pivotal modulators in oncogenesis. Cantley’s discourse elucidates the intricate biochemical networks underpinning kinase activity, emphasizing the therapeutic potential locked within their cellular regulatory mechanisms. This nuanced understanding paves the way for the development of more precise kinase inhibitors, curbing cancer cell proliferation and resistance.

Genomic disparities and their implications on cancer outcomes form a vital theme of the meeting, articulated by Melissa B. Davis, PhD, from Morehouse School of Medicine. Her presentation delves into the systemic inequities embedded within genomic datasets and the consequent population-level cancer disparities. Highlighting the necessity for inclusive genomic research, Davis underscores the role of tailored therapeutic interventions that address the unique molecular profiles of historically underrepresented groups, aiming to reduce the cancer burden equitably across diverse populations.

Another groundbreaking topic is the elucidation of RAS oncogenic signaling pathways and their immune evasion strategies, expertly presented by Julian Downward, PhD, of the Francis Crick Institute. RAS proteins, notorious for their role in driving oncogenesis, have historically been deemed “undruggable” due to their structural complexity. Downward’s insights into the modulation of immune checkpoints and intracellular signaling networks offer promising avenues for therapeutic innovation targeting these elusive oncoproteins, potentially revolutionizing treatment paradigms for RAS-driven malignancies.

The symposium also honors four decades of research on tyrosine phosphorylation, conveyed by Tony Hunter, PhD, from the Salk Institute. Tyrosine phosphorylation, a critical post-translational modification, orchestrates myriad cellular processes including growth and differentiation. Hunter’s retrospective and forward-looking analysis highlights how decades of fundamental biochemical research have culminated in the development of tyrosine kinase inhibitors that have transformed the therapeutic landscape for multiple cancer types, illustrating the profound impact of basic science on clinical advances.

William G. Kaelin Jr., MD, also from Dana-Farber Cancer Institute, addresses the enigmatic VHL (von Hippel-Lindau) tumor suppressor protein. His presentation navigates the complexities of targeting the “undruggable,” focusing on how understanding the VHL pathway’s regulatory role in hypoxia-inducible factors offers unprecedented therapeutic strategies. The molecular intricacies unravelled here hold immense promise in devising treatments that disrupt tumor growth in cancers characterized by VHL inactivation.

Edison T. Liu, MD, of The Jackson Laboratory, brings attention to triple-negative breast cancer (TNBC), a particularly aggressive subtype lacking targeted hormonal therapies. His genomic biology analysis probes the mutational landscape and heterogeneity of TNBC, revealing potential biomarkers and targets for innovative therapies. By integrating genomic sequencing data with clinical phenotypes, Liu’s work exemplifies the precision oncology approach that strives to tailor interventions to the unique genetic makeup of each tumor.

Elaine Mardis, PhD, from The Ohio State University, highlights the genomic diversity observed in acute myeloid leukemia (AML) among Black patients. This focus on genetic variability elucidates treatment outcome disparities and underscores the necessity of incorporating diverse populations in genomic studies. Mardis’s research advocates for personalized medicine strategies that account for racial and ethnic differences in cancer genomics, seeking to optimize therapeutic efficacy and equity.

Continuing at The Ohio State University, W. Kimryn Rathmell, MD, PhD, intriguingly contextualizes the historic and prospective trajectory of UNC Lineberger as a model for comprehensive cancer care. Rathmell’s insights weave together translational research, clinical innovation, and public health initiatives, underscoring the institution’s multifaceted approach to combating cancer. This holistic model exemplifies how integrated efforts enhance patient care and accelerate the translation of discoveries from bench to bedside.

From a public health perspective, Kurt M. Ribisl, PhD, of the UNC Gillings School of Global Public Health, advocates for interdisciplinary strategies in cancer prevention. His discourse emphasizes leveraging epidemiology, behavioral science, and policy to formulate concerted interventions that address cancer risk factors at the population level. Ribisl’s work highlights the critical interface between science and community health, illustrating the importance of preventative frameworks in reducing cancer incidence.

Arlene Sharpe, MD, PhD, of Harvard Medical School, explores the revolutionary use of CRISPR technology in discovering new immunotherapy targets. Her expert analysis demonstrates how genome editing accelerates the identification of molecular pathways that can be manipulated to enhance immune recognition and destruction of cancer cells. Sharpe’s contributions underscore the transformative potential of combining genetic engineering with immuno-oncology to develop next-generation therapies.

Kevan Shokat, PhD, from UC San Francisco, confronts the formidable challenge of drugging K-Ras, a dominant oncogene implicated in numerous cancers. Shokat’s research highlights innovative chemical biology techniques and allosteric modulation approaches that have begun to dismantle previous barriers in targeting K-Ras. His work represents a significant stride towards effective therapeutics against notoriously resistant oncogenic drivers.

Additionally, Melissa Troester, PhD, and Stephanie B. Wheeler, PhD, MPH, both from UNC Gillings School of Global Public Health, champion collaborative frameworks and multimodal data integration to optimize breast cancer care. Troester focuses on harnessing diverse data types—including genomic, histopathologic, and clinical information—to refine prognostic accuracy and treatment personalization. Meanwhile, Wheeler underscores community-engaged approaches and policy initiatives aimed at enhancing cancer care equity within North Carolina.

Kwok-Kin Wong, MD, PhD, of NYU Langone Health, addresses targeted therapeutic strategies for lung squamous cell carcinoma. Highlighting molecular vulnerabilities, Wong’s presentation sheds light on precision medicine approaches that improve outcomes for patients afflicted with this challenging lung cancer subtype.

Finally, Yue Xiong, PhD, from Cullgen Inc., discusses targeted protein degradation as an emerging therapeutic platform. This novel modality leverages the cell’s intrinsic degradation machinery to selectively eliminate oncogenic proteins, presenting a paradigm shift that holds promise across various cancer types.

Collectively, the 48th Annual UNC Lineberger Scientific Symposium integrates an impressive array of scientific advancements and multidisciplinary insights. By traversing molecular biology, clinical research, and population health, the symposium reaffirms its foundational mission: harnessing the full spectrum of cancer research to forge pathways for improved patient outcomes worldwide. Furthermore, the event’s accessibility through livestream and free registration underscores its commitment to disseminating knowledge broadly, fostering global collaboration in the fight against cancer.

Subject of Research: Cancer research continuum including molecular discovery, clinical applications, population health, and therapeutic innovations.

Article Title: Breakthroughs and Perspectives at the 48th Annual UNC Lineberger Scientific Symposium: Advancing the Cancer Research Continuum

Web References:
https://unclineberger.org/symposium/
https://apps2.research.unc.edu/events/index.cfm?event=events.go&key=C96B

Image Credits: UNC Lineberger Comprehensive Cancer Center

Keywords: Cancer, Breast cancer, Leukemia, Pancreatic cancer, Lung cancer

The complexity of solid tumors stems from their heterogeneous population of cells, often numbering in the millions, which poses an ongoing challenge to treatment strategies. Surgical excision or systemic therapies may be effective in controlling primary tumors, yet metastatic dissemination significantly worsens patient prognosis. The researchers focused on circulating tumor cell (CTC) clusters—cohesive groups of cells detaching from the primary neoplasm and found within patient bloodstream samples. These clusters, in contrast to singular tumor cells, exhibit enhanced metastatic potential, yet the molecular and biophysical pathways facilitating their intravasation—penetration into blood vessels—have eluded the scientific community until now.

Addressing this gap, the interdisciplinary team engineered an advanced three-dimensional in vitro model mimicking the tumor microenvironment with unprecedented precision. This "tumor-microvessel on-a-chip" system integrates artificial blood vessels alongside intestinal tumor organoids derived from neoplastic tissue. By carefully manipulating the spatial orientation of these organoids relative to the vessel walls, researchers gained the ability to visualize, in real time, dynamic interactions between tumor cell clusters and the vascular endothelium using high-resolution live-imaging techniques.

What emerged from these observations was a striking phenomenon. Tumor cell clusters displayed directed migration toward the vascular structures, eventually disrupting the integrity of vessel walls to intravasate. Upon entering the lumen of the blood vessel, these cohesive clusters dispersed—likely a prelude to dissemination and colonization at distant sites. The vessel walls themselves revealed molecular transformations indicative of an endothelial-to-mesenchymal transition (EndMT), a cellular reprogramming where endothelial cells lose their characteristic features and adopt a mesenchymal, more malleable state.

Central to this transition was the upregulation of key cytokines, particularly transforming growth factor-beta (TGF-β) and activin, secreted in response to tumor cell cluster proximity. These molecules orchestrate complex signaling cascades that compromise the endothelial barrier function, rendering the vessel walls more permissive to cluster infiltration. Such molecular insight clarifies how tumor clusters effectively "take over" segments of the blood vessel wall to penetrate the bloodstream, a process previously only hypothesized without direct mechanistic evidence.

This discovery holds significant implications for therapeutic development. Preventing or mitigating the intravasation of CTC clusters could curb metastatic spread and improve patient survival rates. The novel 3D in vitro system offers a versatile platform for screening anti-metastatic compounds aimed specifically at interrupting the signaling pathways or mechanical disruptions facilitating vascular entry. Future research leveraging this technology may reveal targeted molecular inhibitors that reinforce endothelial barrier integrity against malignant infiltration.

Moreover, the study underscores the importance of tumor architecture and microenvironmental factors in metastasis. While isolated tumor cells possess metastatic capability, the collective behavior of clusters endows them with unique advantages, such as enhanced survival in circulation and evasion of immune surveillance. By visibly capturing the process of cluster migration, vascular wall disruption, and luminal dissemination within a controlled laboratory setting, the research provides a vital window into the physical and biochemical interplay driving metastatic progression.

Yukinori Ikeda and Makoto Kondo, co-lead authors of the study, emphasize the novelty of their observations: the direct interaction between compact cell groups and vascular endothelial cells, culminating in site-specific partial endothelial disruption followed by cluster dispersal. This process defies traditional views that cancer cells primarily migrate individually, reaffirming that collective cell dynamics are crucial to understanding tumor biology comprehensively.

Senior author Professor Yukiko Matsunaga reflects on the translational potential of these findings, suggesting that clinical strategies focusing on interrupting cluster-mediated metastasis may transform treatment paradigms in advanced cancers. These could include localized delivery of TGF-β inhibitors, enhancement of endothelial junction proteins, or novel biomaterials designed to strengthen vessel walls against tumor-induced breakdown.

Importantly, this study demonstrates the power of organ-on-a-chip technology as an investigative tool. By faithfully reproducing aspects of tumor-vessel interfaces, researchers can dissect cellular behaviors that remain inaccessible within living organisms due to complexity and the invasiveness of traditional sampling. Such systems herald a new era of cancer research where microengineering and cell biology merge to unravel intricate disease mechanisms.

In summary, by unveiling the specific steps and molecular drivers enabling tumor cell clusters to hijack blood vessels and access the circulatory system, this research opens promising pathways toward innovative interventions against cancer metastasis. As metastasis underlies the majority of cancer-related deaths, targeted approaches inspired by these discoveries may dramatically reshape prognostic outlooks for patients worldwide.

Subject of Research: Mechanisms of tumor cell cluster intravasation and metastasis using a 3D tumor-microvessel on-a-chip model.

Article Title: A tumor-microvessel on-a-chip reveals a mechanism for cancer cell cluster intravasation

News Publication Date: 19-May-2025

Web References:
https://doi.org/10.1016/j.isci.2025.112517

Image Credits: Institute of Industrial Science, The University of Tokyo

Keywords: Cell biology, Cancer cells, Blood vessels, Vascular cells, Circulating tumor cells, Endothelial cells